UNIKLINIK RWTH AACHEN
Centrum für Integrierte Onkologie – CIO Aachen

PHASE 1-Studien

MPN

JNJ-88549968

A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms

INCA 33989-101

A Phase 1, Open-Label, Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Accelerated phase MPN (10-19% Blasten PB od. KM)

HOVON 172 MF

A phase 1b/2 trial with tasquinimod in patients with myelofibrosis (primary, post-PV or post-ET) refractory to or intolerant for JAK2 inhibition: the TasqForce trial

INCA036978-101

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

CML

TERN-701
Monotherapie
(Terns, Inc.)

REKRUTIERUNG:
- Received 2 or more TKIs

ELVN-001
Monotherapie
(Enliven)

REKRUTIERUNG:
- CML CP oder AP nach Ausschöpfung alle Therapielinien

AML

AlloTx

FLAMSAClax
Phase I/II
Venetoclax Konditionierung mit Fludarabin/Amsacrin/ AraC(FLAMSA)+Treosulfan für allo TX

REKRUTIERUNG:
- MDS,CMML, sAML

Priv.-Doz. Dr. med. Martina Crysandt mcrysandt@ukaachen.de Tel: 0241-8089759

Stand 10/2026